GLP-1 denials: the most-fought drugs in America — and the appeal record
Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda. No drug class generates more insurance denials right now — and no drug class has a better published appeal record. Across 1,629 published external-review decisions on GLP-1 denials, independent physician reviewers overturned the insurer 86% of the time.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
The record, drug by drug
| Drug | FDA-approved for | Decisions | Overturned |
|---|---|---|---|
| Wegovy | Chronic weight management | 606 | 88.6% |
| Zepbound | Chronic weight management | 574 | 92.3% |
| Mounjaro | Type 2 diabetes | 152 | 67.1% |
| Ozempic | Type 2 diabetes | 139 | 65.5% |
| Wegovy Solution Auto-injector | See Wegovy | 67 | 86.6% |
| Saxenda | Chronic weight management | 46 | 91.3% |
| Zepbound Solution Auto-injector | See Zepbound | 45 | 91.1% |
Why GLP-1 denials happen
GLP-1 receptor agonists are expensive, effective, and in staggering demand — which makes them the exact profile of drug that plans build denial machinery around. Nearly every GLP-1 denial letter falls into one of six patterns, and each has a known counter.
Formulary exclusion of weight-loss drugs
Many plans — especially self-funded employer plans — exclude the entire anti-obesity medication category from the formulary. The letter says “not a covered benefit.” This is the hardest pattern, but not a dead end: appeals dispute whether the exclusion's actual language reaches your prescription, and newer indications (cardiovascular risk reduction, sleep apnea) often fall outside what the exclusion was written to cover.
“Lifestyle” or “cosmetic” exclusions
Some denials classify weight management itself as cosmetic. Obesity is a diagnosed chronic disease with its own ICD codes, and the drugs at issue carry FDA approvals for treating it — plus, for Wegovy and Zepbound, approvals for cardiovascular-risk and sleep-apnea indications that no honest reading calls cosmetic. Reviewers see through this framing, which is part of why overturn rates run so high.
Step therapy
The plan wants documented failure of cheaper options first — a structured diet-and-exercise program, an older weight-loss drug, or (for diabetes) metformin and other preferred agents. Most step-therapy denials are documentation failures, not clinical ones: the trials happened, but nobody put them in the prior-auth request.
BMI and comorbidity documentation requirements
Plan criteria typically track the FDA label's BMI framework, requiring chart-documented BMI and, at lower thresholds, a weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Denials cite what the chart doesn't show — which an appeal can simply supply.
Quantity limits and dose titration
GLP-1s are titrated stepwise to a maintenance dose, and shortage-era substitutions scrambled many regimens. That produces refill and quantity-limit denials that have nothing to do with medical necessity and everything to do with pharmacy plumbing. These resolve through exception requests and appeals at very high rates.
Indication mismatch
The single most preventable GLP-1 denial: a diabetes-labeled drug (Ozempic, Mounjaro) prescribed for weight loss, or coverage criteria applied to the wrong indication. The same molecules carry weight-management approvals under different names — details below, because this is where the data gets interesting.
Same molecule, different label: the cross-indication problem
Two molecules power almost this entire drug class, and each is sold under two names with different FDA approvals:
Insurers know this map cold, and the published review outcomes show exactly how much the label matters. When the weight-management-labeled drugs were denied for obesity, reviewers overturned the plan 94.8% of the time for Zepbound (439 decisions) and 90.7% for Wegovy (486 decisions). When the diabetes-labeled versions were requested for obesity instead, the numbers drop — 73.3% for Ozempic and just 36.7% for Mounjaro, even though Mounjaro denials for its on-label type 2 diabetes indication were overturned 76.5% of the time. The lesson is blunt: fight on-label whenever you can. If the clinical goal is weight management, the on-label semaglutide is Wegovy and the on-label tirzepatide is Zepbound — and appeals for those prescriptions win at some of the highest rates in the entire corpus.
The newer indications also quietly demolish the most common denial rationale. A plan that dismisses semaglutide as a “lifestyle drug” has to contend with Wegovy’s FDA approval for reducing cardiovascular events in adults with heart disease. A plan calling tirzepatide cosmetic has to explain Zepbound’s approval for obstructive sleep apnea — an indication where reviewers overturned 77.8% of published denials. If you qualify for one of these indications, lead with it.
What a winning GLP-1 appeal argues
The overturned decisions in the corpus follow a recognizable playbook. The first move is diagnostic: figure out whether you’re fighting a medical-necessity denial(the plan covers the drug class but says you don’t qualify) or a benefit-exclusion denial(the plan says the category isn’t covered at all). They’re different fights.
Against medical-necessity denials: meet the criteria point-by-point
Demand the plan's specific clinical criteria — you're entitled to them. Then have your treating physician answer each criterion directly: documented BMI history, weight-related comorbidities, A1C and diagnosis for the diabetes drugs, and the clinical goal of therapy. Reviewers overturn plans that applied criteria mechanically to an incomplete chart.
Against step-therapy denials: document the failures
List every prior attempt with specifics — program or drug, dates, duration, outcome, side effects. Then invoke the plan's step-therapy exception process, which most states and plan types require, with short mandatory decision deadlines. A prescriber attestation that alternatives failed or are clinically inappropriate is the standard winning ground.
Against exclusions: attack the language, not the policy
Make the plan quote the exact exclusion text. Then test it: does it reach a drug prescribed for cardiovascular risk reduction? For obstructive sleep apnea? For a chronic disease with its own diagnosis codes? Exclusions written to block “cosmetic weight loss” often don't cleanly cover what was actually prescribed — and ambiguity gets argued against the drafter.
Always: the treating-physician letter
The single highest-leverage document in the packet. It should tie the patient's chart to the plan's criteria, state the FDA-approved indication being treated, recount prior failures, and say plainly why this drug, at this dose, now.
Who regulates your plan changes the fight
The same Wegovy prescription can be an easy approval under one plan and a categorical exclusion under another, because GLP-1 coverage is decided plan by plan — and the rules that police the plan depend on who regulates it.
- Employer coverage is usually a self-funded plan governed by federal ERISA rules. The employer — not the insurer whose logo is on the card — chose whether to buy the weight-loss drug benefit, and appeals run through a federally required internal process followed by independent external review. HR benefit-exception requests are a real parallel track here. ERISA appeal rights.
- ACA marketplace and other state-regulated plans answer to state insurance law: step-therapy exception statutes, mandated decision deadlines, and the state external-review process that produced the numbers on this page. Marketplace appeal rights.
- Medicaiddrug coverage is set state by state; GLP-1s prescribed for type 2 diabetes are widely covered, while anti-obesity coverage varies with the state’s program. Fair-hearing rights apply to denials. Medicaid appeal rights.
- Medicare Advantagehas its own multi-level appeal ladder: if the plan doesn’t fully rule in your favor, your case is automatically forwarded to an independent reviewer. Medicare Advantage appeal rights.
Identify your plan type before you write a word of the appeal — it determines your deadlines, your reviewer, and which exception statutes you can invoke.
The documentation that decides these cases
Across the overturned decisions, the pattern is consistent: reviewers reverse plans when the record is complete. Before filing, assemble:
- The denial letter itself, plus the plan's clinical criteria for the drug (request them in writing — you are entitled to them).
- Chart-documented BMI history, and for the diabetes drugs, diagnosis codes and A1C values over time.
- Weight-related comorbidities with dates: hypertension, dyslipidemia, sleep apnea, joint disease, fatty liver disease — whatever the chart supports.
- Every prior weight-management or glycemic-control attempt: program names, medications, doses, duration, outcome, side effects.
- A treating-physician letter that walks the plan's criteria point by point and states the FDA-approved indication being treated.
- For sleep-apnea cases: the sleep study. For cardiovascular cases: the cardiac history. Lead with the indication the exclusion can't reach.
Medicare Part D has historically excluded drugs used for weight loss, while covering GLP-1s prescribed for type 2 diabetes. Coverage rules for anti-obesity medication are changing — check your plan’s current formulary and criteria rather than assuming either answer. Medicare Advantage members also have unusually strong appeal machinery: see how Medicare Advantage appeals work.
If the internal appeal fails: external review
Every number on this page comes from external review — the stage after the insurer denies your internal appeal, where an independent physician panel re-decides the case and the decision binds the insurer. California’s program publishes its outcomes, which is why we can show you the record; every state runs an equivalent process, and federal rules guarantee one for most plan types. Deadlines are real (commonly four months to four years depending on the program, and much shorter for the internal appeal that comes first), so check your appeal rights by plan type and state.
Related reading: prior-authorization denials · “not medically necessary” denials · “not a covered benefit” denials · obesity denial outcomes · all treatments
GLP-1 denial FAQ
Yes. A plan exclusion narrows your arguments but doesn't end them. Appeals challenge whether the exclusion actually applies (Wegovy has a cardiovascular indication and Zepbound a sleep-apnea indication that weight-loss exclusions weren't written to reach), whether the plan quoted real exclusion language, and whether state or federal rules limit the exclusion. In the published California external-review record, the large majority of GLP-1 denials taken to review were overturned.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. When the diagnosis on the request is obesity rather than diabetes, plans deny for indication mismatch — and reviewers side with plans on off-label weight-loss requests far more often than on diabetes requests. The same molecules are approved for chronic weight management as Wegovy (semaglutide) and Zepbound (tirzepatide); an on-label prescription is a much stronger position.
The pattern across overturned decisions: a treating-physician letter tied to the plan's own criteria, chart documentation of BMI and weight-related comorbidities (or A1C and diagnosis for diabetes drugs), a specific account of prior treatments tried and failed for step-therapy rules, and the FDA-approved indication stated plainly. Appeals that force the plan to quote its exact criteria language do best.
Medicare Part D has historically excluded drugs used for weight loss, while covering GLP-1s prescribed for type 2 diabetes. Coverage rules for anti-obesity medication are changing — check your specific plan's current formulary and criteria before assuming either answer.
Internal-appeal deadlines are commonly 180 days from the denial notice for employer and marketplace plans, and 60 days for Medicare Advantage — but your denial letter's stated deadline controls, so read it. External-review windows after the internal denial vary by state and plan type. If you're mid-titration or your health is at risk from delay, request an expedited appeal, which compresses the decision timeline to days.
No. Appeals are a consumer process by design: a letter, supporting records, and your plan's own criteria. The strongest inputs are your treating physician's letter and organized documentation, not legal argument. Lawyers matter in edge cases — large claims, bad-faith patterns, ERISA litigation after appeals are exhausted — but the published overturn record is built overwhelmingly on ordinary appeals filed by patients and doctors.
Every state gives you the right to an external review by an independent physician panel whose decision binds the insurer, and most federal plan types have an equivalent. The statistics on this page are the published outcomes of exactly that process — and they run heavily against the insurer.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY